Pharmaceutical giant Novartis (NYSE:NVS) announced in a press release Tuesday that the European Commission has granted approval for the company's vaccine for meningitis B (menB), Bexsero. It is the first approved vaccine for treating broad cases of this type of meningitis.
A European panel earlier backed Bexsero's approval bid in November 2012. The company plans to make Bexsero available as soon as possible in Europe, noting that menB is the leading cause of meningitis death in the continent. According to the release, Novartis has begun negotiating with European nations interested in including Bexsero in national immunization programs.
Andrin Oswald, head of Novartis' Vaccines and Diagnostics Division, is quoted in the company press release as saying, "Our vision is a world without meningitis, and our priority is to work with decision makers across Europe to ensure there is broad and timely access to vaccination."
Peak sales estimates vary, with projections of $700 million annually on the low end increasing to high-end estimates of $1 billion or more within the decade.
Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Generic Drug Stocks to Consider Buying Now
Want to cash in on the pharmaceutical boom? Generic drugs add to the arguments for giving Pfizer, Novartis and Mylan a closer look.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Here Are the Big Pharma Stocks to Own Based on R&D Spending
Roche, Novartis, Pfizer, Johnson & Johnson, and Merck are investing the heaviest in R&D. That could bode well for these big pharma stocks.